Investor Relations

The Board

Home>Corporate Governance>The Board

WANG Chuncheng - Chairman of the Board and Non-executive Director

Mr. WANG Chuncheng, serves as an executive vice president of China Resources (Holdings) Company Limited (“CR Holdings”), concurrently serves as the chairman of the Board of China Resources Pharmaceutical Group Limited and also serves as the chairman of China Resources Sanjiu Medical & Pharmaceutical Company Limited (“CR Sanjiu”), a company listed on Shenzhen Stock Exchange (stock code: 000999) and the chairman of China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (我司江中制药集团有限责任公司). Mr. WANG has over 20 years of experience in corporate management, Mr. WANG holds a bachelor’s degree in economics from Jilin Institute of Finance and Trade (currently known as Jilin University of Finance and Economics). He joined CR Holdings in 1997.

HAN Yuewei - Executive Director

Mr. HAN Yuewei, was appointed as an executive Director, chief executive officer of the Company in October 2019. He also serves as the chairman of Dong-E-E-Jiao Company Limited（東阿阿膠股份有限公司）(“Dong-E-E-Jiao”) (the shares of which are listed on the Shenzhen Stock Exchange, Stock Code: 000423), and a director of CR Sanjiu and a director of China Resources Double-Crane Pharmaceutical Company Limited（華潤雙鶴藥業股份有限公司）(“CR Double-Crane”) (the shares of which are listed on the Shanghai Stock Exchange, Stock Code: 600062). Mr. HAN served as an executive director of China Resources Medical Holdings Company Limited (“CR Medical”) (listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), stock code: 1515) from October 2017 to October 2019, during which he served as the chief executive officer of CR Medical and the general manager of China Resources Healthcare Group Limited, the controlling shareholder of CR Medical. Mr. HAN worked for China Resources Land Limited (“CR Land”) (listed on the Stock Exchange, stock code: 1109) from October 2010 to October 2017, during which he served as deputy general manager of Shenyang Region, deputy general manager of Shenzhen Region, director of engineering and vice president of CR Land. Prior to joining CR Land, Mr. HAN worked as the deputy director and director of the Bureau of Public Works of Shenzhen Municipality（深圳市建築工務署）from April 2002 to October 2010. Mr. HAN obtained a master’s degree in construction economics and management from Tsinghua University（清華大學）and a bachelor’s degree in construction management from Tsinghua University in July 1993 and July 1991 respectively.

LI Xiangming - Vice Chairman of the Board and Executive Director

Mr. LI Xiangming, was appointed as an executive Director in May 2019 and subsequently appointed as vice chairman of the Board in December 2019. Mr. LI was appointed as the chairman of China Resources Pharmaceutical Commercial Group Company Limited (“CR Pharmaceutical Commercial”) (a wholly owned subsidiary of the Company) in February 2019. Mr. LI currently serves as a vice president of China Association of Pharmaceutical Commerce and a chief supervisor of Beijing Pharmaceutical Association. From December 2015 to February 2019, Mr. LI successively served as party committee vice secretary, executive deputy general manager and party committee member of the Company and party committee secretary and general manager of CR Pharmaceutical Commercial. Mr. LI is a traditional Chinese pharmacist. He obtained an EMBA degree from University of International Business and Economics, China.

WENG Jingwen - Executive Director

Mdm. WENG Jingwen, was appointed as an executive Director, chief financial officer and vice president of the Company in July 2019, has 12 years of experience in financial management and auditing and 8 years of experience in strategic development and business analysis. Mdm. WENG also serves as a director of Dong-E-E-Jiao, a director of CR Double Crane and a supervisor of CR Sanjiu. She served as a director of CR Sanjiu from December 2015 to November 2019. Mdm. WENG joined China Resources Group in 2004 and served as a general manager of internal audit department and strategic controller of China Resources Gas Group Limited (the shares of which are listed on the Stock Exchange), Stock Code: 1193), deputy strategic development controller of China Resources (Holdings) Company Limited (with a focus in pharmaceutical and healthcare areas). Mdm. WENG was previously engaged in financial management and auditing job in the International Business Machines Corporation and PricewaterhouseCoopers before joining China Resources Group. Mdm. WENG obtained a bachelor’s degree in economics from Zhejiang University and an MBA degree from the Hong Kong University of Science and Technology.

YU Zhongliang - Non-executive Director

Mr. YU Zhongliang, was appointed as a non-executive Director in June 2016. Mr. YU also serves as a senior deputy chief strategy officer of the Strategy Management Department of CR Holdings. Mr. YU has over 30 years of experience in investment, business analysis and strategic development. Mr. YU was successively the strategic development controller, an executive director and a vice chairman of China Resources Cement Holdings Limited, a company listed on the Stock Exchange (stock code: 1313). Mr. YU holds an MBA degree of York University in Toronto, Canada.

GUO Wei - Non-executive Director

Mdm. GUO Wei, was appointed as a deputy financial director of the Finance Department of CR Holdings in April 2017. Mdm. GUO has been a director of CR Sanjiu since April 2018 and has been a director of CR Double-Crane since December 2015. Mdm. GUO holds a bachelor’s degree in economics from University of International Business and Economics, China and a master’s degree in law from Peking University, China.

WANG Shouye - Non-executive Director

Mr. WANG Shouye, joined the Beijing State-Owned Capital Operations and Management Centre (“BSCOMC”) in 2010 and is currently the chief financial officer of BSCOMC. He was a director of the Company from October 2011 to June 2016. Mr. WANG was also a non-executive director of CSC Financial Co., Ltd., a company listed on the Stock Exchange (stock code: 6066), from August 2016 to February 2018. Mr. WANG has over 10 years of experience in financial management. He was the director of finance and audit division of Beijing Coal Corporation, the director of finance and audit division, the director of finance and audit department, the director of finance department, and the director of finance and price department of Beijing Jintai Hengye Co., Ltd.（北京金泰恒业有限责任公司）, a subsidiary of Beijing Jingmei Group Co. Ltd.（北京京煤集团有限责任公司）and the director of finance department of Beijing Golden Tide Group Co. Ltd（北京金泰集团有限公司）, a subsidiary of Beijing Jingmei Group Co. Ltd.（北京京煤集团有限责任公司）. Mr. WANG graduated from Fuxin Mining Institute majoring in statistics in 1992 and graduated from the School of Continuing Education of Renmin University of China on a part-time basis in 1997 majoring in investment and economics management. Mr. WANG obtained a master’s degree in business management and economics from Liaoning Technical University in 2006. He is also a senior accountant and senior statistician in the PRC.

LYU Ruizhi - Non-executive Director

Mr. LYU Ruizhi, joined BSCOMC in 2010 and is currently the general manager of the investment management second division of BSCOMC. Mr. LYU has many years of experience in investment management. He was the vice manager of the securities department of Beijing Capital Development Co., Ltd.（北京首都开发股份有限公司）and the vice general manager of the investment management division of BSCOMC. Mr. LYU was a part-time director of Beiqi Foton Motor Co., Ltd (北汽福田汽车股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 600166) from September 2015 to July 2018. Mr. LYU graduated from the department of investment economics of Renmin University of China in 1995 majoring in investment economics management and obtained a master’s degree in accounting from the School of Business of Renmin University of China in 2002. He is also an economist in the PRC.

SHING Mo Han Yvonne - Independent Non-executive Director

Mdm. SHING Mo Han Yvonne, BBS, JP, was appointed as an independent non-executive Director in August 2017. Mdm. SHING was appointed as a Justice of Peace of the HKSAR in 2013 and awarded Bronze Bauhinia Star in 2017. Mdm. SHING is currently the chairman of Yinn Advisory Services Limited and an independent non-executive director of CSSC (Hong Kong) Shipping Company Limited (listed on the Stock Exchange, stock code: 3877). Mdm. SHING was a partner of Deloitte China for over 26 years until her retirement in May 2016. She is also a member of the 10th, 11th and 12th Jiangsu Provincial Committee of the CPPCC. Mdm. SHING is a founding member and past president of the Association of Women Accountants (Hong Kong) and the past chairman of Hong Kong Institute of Certified Public Accountants Taxation Committee. She is now the vice-chairman of Hong Kong General Chamber of Commerce Tax Committee and member of Chinese General Chamber of Commerce. Her professional qualifications include fellow member of the Hong Kong Institute of Certified Public Accountants, Association of Chartered Certified Accountants and Institute of Chartered Secretaries and Administrators. Mdm. SHING’s current public appointments include treasurer of the Council of the Hong Kong Academy for Performing Arts, member of the Corruption Prevention Advisory Committee of the Independent Commission Against Corruption, member of the Communications Authority, member of the Advisory Committee on Built Heritage Conservation, court member of the Hong Kong Polytechnic University, and advisor and member of the Finance Committee of Our Hong Kong Foundation. In 2006, Mdm. SHING received the National Hundred Outstanding Women Entrepreneurs Award in Great Hall of the People in Beijing. She also received the Outstanding Alumni Award of Hong Kong Polytechnic University in 2007. Mdm. SHING has been consecutively named from 2001 to 2015 in International Tax Review as one of the World’s Leading Tax Advisors in Hong Kong and Mainland. Mdm. SHING graduated from the Hong Kong Polytechnic (currently known as the Hong Kong Polytechnic University) and obtained a Higher Diploma in Accountancy and is 2016/2017 University Fellow of the Hong Kong Polytechnic University.

KWOK Kin Fun - Independent Non-executive Director

Mr. KWOK Kin Fun, BBS, JP, was appointed as an independent non-executive Director in June 2016. Mr. KWOK also serves as an Executive Committee member of Rehabilitation International and global Vice Chairman of Social Commission of Rehabilitation International, the chairman of Incheon Strategy Group Committee of Asia and Pacific Disability Forum, a vice chairman of The Hong Kong Joint Council for People with Disabilities, a vice chairman of The Hong Kong Society for Rehabilitation, the chairman of Fu Hong Society, a member of Ethics Research Committee of Hospital Authority Kowloon Central and Kowloon East Clusters, a member of Voting Members Committee of Riding For the Disabled Association, the chairman of Accessible IT Development Association Limited. Mr. KWOK has over 30 years of experience in disability research and medical research ethics. He successively served as a senior lecturer, a principal lecturer, a university senior lecturer and an associate professor of the City University of Hong Kong from 1985 to 2009, and after retirement served as full-time and part-time senior research fellow. Mr. KWOK was appointed as a Justice of the Peace by the government of Hong Kong in 1997 and received the Bronze Bauhinia Star awarded by the government of Hong Kong SAR in 2005, “Kazuo Itoga” Memorial Prize awarded by the government of Shiga Prefecture, Japan in 2006, and the Promoter title of “Asian and Pacific Decade of Persons with Disabilities, 2013–2022” awarded by United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) in 2012. Mr. KWOK holds a bachelor’s degree in social science from the University of Hong Kong, a master’s degree in social science from the Chinese University of Hong Kong, and a Ph.D. degree from the University of Nottingham, the UK.

FU Tingmei - Independent Non-executive Director

Mr. FU Tingmei, was appointed as an independent non-executive Director in June 2016. Mr. FU has over 20 years of experience in investment, finance, law and business management. Mr. FU currently serves as an independent non-executive director of Guotai Junan International Holdings Limited, a company listed on the Stock Exchange (stock code: 1788), Postal Savings Bank of China Co., Ltd., a company listed on the Stock Exchange (stock code: 1658) and COFCO Meat Holdings Limited, a company listed on the Stock Exchange (stock code: 1610). Mr. FU was an independent non-executive director of Beijing Enterprises Holdings Limited, a company listed on the Stock Exchange (stock code: 0392) from July 2008 to June 2017 and an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange (stock code: 0906) from June 2008 to July 2019. Mr. FU holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom.

ZHANG Kejian - Independent Non-executive Director

Mr. ZHANG Kejian, was appointed as an independent non-executive Director in June 2016. Mr. ZHANG also serves as an independent director of Yifan Pharmaceutical Co., Ltd. (a company listed on Shenzhen Stock Exchange, stock code: 002019), an independent director of Hunan Fangsheng Pharmaceutical Co., Ltd (a company listed on Shanghai Stock Exchange, stock code: 603998) , an independent director of Zhejiang Hisoar Pharmaceutical Co. Ltd. (a company listed on Shenzhen Stock Exchange, stock code: 002099) and the Chief Scientist of The South China Center for Innovative Pharmaceuticals. Mr. ZHANG has over 20 years of experience in the pharmaceutical industry of PRC. He was an independent director of CR Double-Crane, a company listed on Shanghai Stock Exchange (stock code: 600062) from February 2016 to June 2018. He was employed as a professor of School of Pharmaceutical Sciences of Sun Yat-sen University and the director (Pharmacy Administration) of The South China Center for Innovative Pharmaceuticals, a researcher at the Institute of Medicine, Chinese Academy of Medical Sciences（中国医学科学院药物研究所）, and successively served as a deputy director of Pharmaceutical Evaluation Center（药品审评中心）and a deputy director of Medical Device Evaluation Center（医疗器械技术审评中心）under the State Food and Drug Administration of the PRC（国家食品药品监督管理局）. Mr. ZHANG received a master’s degree in pathophysiology from China Medical University in Shenyang, the PRC and a doctor’s degree in pharmacy from the School of Pharmaceutical Sciences of Chiba University in Chiba, Japan.